Table 1:

Clinical approaches to targeting OXPHOS in Leukemias

Therapy	Drug Target	Cancer Type	Trial Reference
Tigecycline	Mitochondrial translation	AML	NCT01332786
Venetoclax with hypomethylating agents	BCL2 and DNA methylation	AML CLL (approved)	NCT02203773
Omacetaxine	Protein Translation	MDS	NCT03564873
ICAS-010759	Electron transport chain Complex I	AML	NCT02882321

While many trials have been designed to target CSCs or metabolism, few have by design specifically target OXPHOS in LSCs. The studies listed in the table represent initial efforts to modulate CSC metabolism.